Skip to content
OpenCapital
Get started

Xencor XNCR Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$359M+63.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
——
Precigen logo
PrecigenPGEN
——

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.09B+79.8%
Enterprise value$1.25B+58.6%
P/S11.2×+6.4×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's proceeds from sale and maturity of available for sale securities?
Xencor (XNCR) reported proceeds from sale and maturity of available for sale securities of $99.97M in Q1 2026.
How has Xencor's proceeds from sale and maturity of available for sale securities changed year-over-year?
Xencor's proceeds from sale and maturity of available for sale securities decreased by 16.0% year-over-year, from $118.99M to $99.97M.
What is the long-term trend for Xencor's proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Xencor's proceeds from sale and maturity of available for sale securities has grown at a -4.4% compound annual growth rate (CAGR), from $485.15M to $405.09M.